Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study.

Nicholas H B SchräderEmily S GorellRoy E StewartJosé C DuipmansNicole HarrisVictoria A PerezJean Y TangAndré P WolffMarieke C Bolling

Published in: Orphanet journal of rare diseases (2021)

CBMs improve the perception of pain, pruritus, wound healing, and well-being in EB patients and reduced concomitant medication use. Nevertheless, a direct relation between the use of CBMs and reduction of the above-mentioned symptoms cannot be proven by these data. Therefore, future controlled studies using pharmaceutically standardised CBM preparations in EB are warranted to delineate the risks and benefits of CBMs.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
wound healing
chronic pain
prognostic factors
electronic health record
machine learning
patient reported outcomes
current status
big data
neuropathic pain
deep learning
sleep quality
artificial intelligence